Activated Src protein tyrosine kinase is overexpressed in late-stage human ovarian cancers

Gynecologic Oncology

Volumn 88, Issue 1, 2003, Pages 73-79

  Wiener, Jon R ^a,b,c   Windham, Christopher ^a   Estrella, Veronica C ^a,b   Parikh, Nila U ^a   Thall, Peter F ^a,b   Deavers, Michael T ^a   Bast Jr , Robert C ^a   Mills, Gordon B ^a,b   Gallick, Gary E ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Immuno histochemistry; Monoclonal antibody; Ovarian cancer; Src; Tyrosine kinase; Yes

Indexed keywords

PROTEIN TYROSINE KINASE;

ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OVARY CANCER; OVARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 0037229627     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2002.6851     Document Type: Article

References (27)

1. Bast RC Jr, Xu F, Yu Y, Fang XJ, Wiener JR, Mills GB. Overview: The molecular biology of ovarian cancer. In: Sharp F, Blackett T, Berek, J, and Bast R, editors. Ovarian Cancer. Vol. 5. Oxford, UK: Isis Medical Media Publishers, 1998: 87-97.
2. c-src family of protein-tyrosine kinases: Structure, regulation, and function. Crit Rev Oncogenesis 1992;3(4):401-46.
3. c-src protein kinase activity in human colon carcinoma. Proc Natl Acad Sci USA 1987;84:2251-6.
4. c-src protein kinase is an early event in colonic carcinogenesis. Proc Natl Acad Sci USA 1990;87:558-62.
5. Lutz MP, Silke Eber IB, Flossmann-Kast BBM, Vogelmann R, Luhrs H, Friess H, Buchler MW, Adler G. Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun 1998;243:503-8.
6. Muthaswamy SK, Siegel PM, Dankort DL, Webster MA, Muller WJ. Mammary tumors expressing the neu proto-oncogene possess elevated c-src tyrosine kinase activity. Mol Cell Biol 1994;14:735-43.
7. Verbeek BS, Vroom TM, Adriaansen-Slot SS, Ottenhoff-Kalff AE, Geertzema JGN, Hennipman A, Rijksen G. c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996;180:383-8.
8. Brown MT, Cooper JA. Regulation, substrates, and functions of src. Biochim Biophys Acta 1996;1287:121-49.
9. c-src with two major signaling pathways in human breast cancer. Proc Natl Acad Sci USA 1994;91:83-7.
10. Biscardi JS, Belsches AP, Parsons SJ. Characterization of human epidermal growth factor receptor and c-src interactions in human breast tumor cells. Mol Carcinogenesis 1998;21:261-72.
11. Muthuswamy SK, Muller WJ. Direct and specific interaction of c-src with neu is involved in signaling by the epidermal growth factor receptor. Oncogene 1995;11:271-9.
12. Wiener JR, Nakano K, Kruzelock RP, Bucana CD, Bast RC Jr, Gallick GE. Decreased src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin Cancer Res 1999;5:2164-70.
13. Kawakatsu H, Sakai T, Takagaki Y, Shinoda Y, Saito M, Owada MK, Yano J. A new monoclonal antibody which selectively recognizes the active form of src tyrosine kinase. J Biol Chem 1996;271(10):5680-5.
14. Kruk PA, Maines-Bandiera SL, Auersperg N. A simplified method to culture human ovarian surface epithelium. Lab Invest 1990;63(1):132-6.
15. Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981;68:1331-7.
16. c-src protein tyrosine kinase activity than do differentiated enterocytes. Oncogene 1993;8:1033-9.
17. Guy CT, Muthuswamy SK, Cardiff RD, Soriano P, Muller WJ. Activation of the c-src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev 1994;8(1):23-32.
18. Staley CA, Parikh NU, Gallick GE. Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific for c-src. Cell Growth Differ 1997;8:269-74.
19. Sakai T, Kawakatsu H, Fujita M, Yano J, Owada MK. An epitope localized in c-src negative regulatory domain is a potential marker in early stage of colonic neoplasms. Lab Invest 1998;78(2):219-25.
20. Parsons JT, Parsons SJ. Src family protein tyrosine kinases: Cooperative with growth factor and adhesion signaling pathways. Curr Opin Cell Biol 1997;9:187-92.
21. 1101 is associated with modulation of receptor function. J Biol Chem 1999;274(12):8335-43.
22. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12.
23. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie S, Yin S, Bast RC Jr. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 1990;50:4087-91
24. Torre EA, Salimbeni V, Fulco RA. The erbB2 oncogene and chemotherapy: A mini-review. J Chemother 1997;9(1):51-5.
25. Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res 1997;57:1199-205.
26. Maa M-C, Leu T-H, McCarley DJ, Schatzman RC, Parsons SJ. Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: Implications for the etiology of multiple human cancers. Proc Natl Acad Sci USA 1995;92:6981-5.
27. Allgayer H, Boyd D, Heiss MM, Abdalla EK, Curley SA, Gallick GE. Activation of src kinase in primary colorectal carcinoma: An indicator of poor clinical prognosis. Cancer 2002;94(2):344-51.